DCGI Banned Sibutramine
Sibutramine, an anti-obesity drug was baned by DGCI.
The Drug Controller General of India (DCGI) on 22 November 2010 banned manufacturing and sale of anti-obesity medicine Sibutramine and its combination drugs sold under various brands as a result of side effects in consumers. The ban follows the recommendation of an expert committee that came out on 12 November to suspend the drug. The committee was set up immediately after Sibutramine’s innovator company US-based Abbott Laboratories withdrew its brand from the Indian market on 25 October 2010. Abbott’s brand Leptos accounted for about a third of the 30 crore market of the drug. Indian drugmakers such as Microlabs, Emcure and Cipla also sell their own brands of Sibutramine. Sibutramine is the third drug used for treating diabetes and obesity that has been banned in India in the past two years. In October 2010 the DCGI had banned the import and manufacture of Rosiglitazone, an anti-diabetic drug due to adverse side effects.